Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-33.96% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
BGLC · Jun 30, 2024
BioNexus Gene Lab Corp. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001477932-24-004792General Corporate
Evidence method
Yoy · gp.fundamentals.revenue
-23.07% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
52.32% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
14.62% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
13.13% · CORE · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History29 statesSelf-history eligible
Sep 30, 20214/6 normalizedLevel 3Dec 31, 20214/6 normalizedLevel 3Mar 31, 20225/6 normalizedLevel 3Jun 30, 20225/6 normalizedLevel 3Sep 30, 20226/6 normalizedLevel 3Dec 31, 20226/6 normalizedLevel 3Mar 31, 20236/6 normalizedLevel 3Jun 30, 20236/6 normalizedLevel 3Sep 30, 20236/6 normalizedAmended as filedDec 31, 20236/6 normalizedLevel 3Mar 31, 20245/5 normalizedLevel 3Jun 30, 20245/5 normalizedLevel 3Sep 30, 20245/5 normalizedLevel 3Dec 31, 20246/8 normalizedLevel 3Mar 31, 20256/7 normalizedLevel 3Jun 30, 20256/7 normalizedLevel 3Sep 30, 20256/7 normalizedLevel 3Dec 31, 20256/9 normalizedLevel 3Mar 31, 20266/7 normalizedLevel 3Jun 30, 20266/7 normalizedLevel 4
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.